Glaxo Inc.

Trimeris, Inc.

M Ross Johnson

Michael G Evans

Jeffrey M Besterman

Michael Luzzio

Dennis Michael Lambert

Milana Dezube

Salvatore Profeta, Jr

Michael Robert Peel

Daniel D Sternbach

Michael J Luzzi

Novel antiviral combinations for the treatment or prevention of viral infections, in particular, HIV, are disclosed. This new antiviral therapy employs either DP-178 or DP-107, viral fusion inhibitors, in combination with at least one other antiviral therapeutic agent. The combinations of the invention are better than single therapies alone, and in certain cases are synergistic. The use of DP-178 or DP-107 is an ideal therapy to combine with another antiviral, given both the novel mechanism which this therapeutic blocks HIV transmission and the non-toxicity of the therapeutic.

Methods and compositions for treatment of HIV-1 infection using antiviral compounds in simultaneous or sequential combinations

Treatment of HIV and other viral infections using combinatorial therapy

The present invention relates to certain substituted tetracyclic fused quinoline derivatives of formula (I): ##STR1## wherein: R.sup.1 is hydrogen, hydroxy, fluoro, chloro, bromo, iodo, methoxy or amino;

Cyclic antitumor compounds

This invention relates to a new process for preparing certain optically active cyclopentene derivatives and novel intermediates used in this process. In particular, the invention concerns the synthesis of the 1'R-cis isomer of carbovir, (1'R-cis)-2-amino-1,9-dihydro-9[4-(hydroxymethyl)-2-cyclopenten-1-yl]-6H-p urin-6-one, an antiviral agent.

Process for the synthesis of cyclopentene derivatives of purines

The present invention relates to the compounds of formula (I), ##STR1## wherein: R.sup.1 is hydrogen, hydroxy or amino;

Antitumor compounds

Growing community of inventors

Chapel Hill, NC, United States of America

M Ross Johnson